Alka-seltzer Original Tablet, Effervescent
NDC Package 85237-1829-1
Package Information
Alka-seltzer Original (anhydrous citric acid, aspirin, and sodium bicarbonate) tablets is directions● fully dissolve 2 tablets in 4 ounces of water before takingadults and children 12 years and over2 tablets every 4 hours, or as directed by a doctordo not exceed 8 tablets in 24 hoursadults 60 years and over2 tablets every 4 hours, or as directed by a doctordo not exceed 4 tablets in 24 hourschildren under 12 yearsconsult a doctor. This formulation utilizes a tablet, effervescent delivery system. Marketed by Select Consumer Group, this product is identified by NDC 85237-1829 and is authorized under FDA application M013.
Identification & Billing
- RxCUI: 1536675 - aspirin 325 MG / citric acid 1000 MG / sodium bicarbonate 1916 MG Effervescent Oral Tablet
- RxCUI: 1536675 - ASA 325 MG / Citric Acid 1000 MG / NaHCO3 1916 MG Effervescent Oral Tablet
- RxCUI: 1536680 - Alka-Seltzer 325 MG / 1000 MG / 1916 MG Effervescent Oral Tablet
- RxCUI: 1536680 - aspirin 325 MG / citric acid 1000 MG / sodium bicarbonate 1916 MG Effervescent Oral Tablet [Alka-Seltzer]
- RxCUI: 1536680 - Alka-Seltzer (aspirin 325 MG / citric acid 1000 MG / sodium bicarbonate 1916 MG) Effervescent Oral Tablet
Clinical Specifications
- Acidifying Activity - [MoA] (Mechanism of Action)
- Alkalinizing Activity - [MoA] (Mechanism of Action)
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Anti-coagulant - [EPC] (Established Pharmacologic Class)
- Calcium Chelating Activity - [MoA] (Mechanism of Action)
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Decreased Platelet Aggregation - [PE] (Physiologic Effect)
- Decreased Prostaglandin Production - [PE] (Physiologic Effect)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 85237 - Select Consumer Group
- 85237-1829 - Alka-seltzer Original
- 85237-1829-1 - 1 POUCH in 1 BLISTER PACK / 2 TABLET, EFFERVESCENT in 1 POUCH
- 85237-1829 - Alka-seltzer Original
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 85237-1829-1 identifies a specific commercial package of 1 pouch in 1 blister pack / 2 tablet, effervescent in 1 pouch of Alka-seltzer Original, a human over the counter drug labeled by Select Consumer Group. This tablet, effervescent is formulated for oral use and contains anhydrous citric acid; aspirin; sodium bicarbonate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Select Consumer Group on March 02, 2010. The current certification is valid through December 31, 2026.
How is this Select Consumer Group product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 85237182901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.